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http://www.lipidworld.com/content/12/1/165RESEARCH Open AccessNrf2 deletion causes “benign” simple steatosis to
develop into nonalcoholic steatohepatitis in mice
fed a high-fat diet
Chunhua Wang, Yizhe Cui, Chunyan Li, Yanhua Zhang, Shang Xu, Xiaochong Li, Hong Li and Xiuying Zhang*Abstract
Background: Nonalcoholic fatty liver disease begins with the aberrant accumulation of triglyceride in the liver. Its
spectrum includes the earliest stage of hepatic simple steatosis (SS), nonalcoholic steatohepatitis (NASH), cirrhosis,
and hepatocellular carcinoma. Generally, hepatic SS is often self-limited; however 10%-30% of patients with hepatic
SS progress to NASH. The cause(s) of the transition from SS to NASH are unclear. We aimed to test the contribution
of nuclear erythroid 2-related factor 2 (Nrf2) on the progression of “benign” SS to NASH in mice fed a high fat diet.
In doing so, we discovered the influence of fatty acid in that progression.
Method: The involvement of Nrf2 in defending against the development of NASH was studied in an experimental
model induced by a high-fat diet. Wild-type and Nrf2-null mice were fed the diet. Their specimens were analyzed
for pathology as well as for fatty acid content and ratios.
Result: In feeding the high-fat diet to the Wild-type and the Nrf2-null mice, the Wild-type mice increased hepatic
fat deposition without inflammation or fibrosis (i.e., simple steatosis), while the Nrf2-null mice had significantly more
hepatic steatosis and substantial inflammation, (i.e., nonalcoholic steatohepatitis). In addition, as a result of the high-fat
diet, SFA (C20: 0, C22: 0) and MUFA (C18: 1, C20: 1) content in Nrf2-null mice were significantly higher than in
Wild-type mice. In the Nrf2-null mice the PUFA/TFA ratio decreased; conversely, the MUFA/TFA ratio increased.
Conclusion: The deletion of Nrf2 causes “benign” SS to develop into NASH in mice fed with a high-fat diet,
through prompt fatty acid accumulation and disruption of hepatic fatty acid composition in the liver.
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Nonalcoholic fatty liver disease (NAFLD) is a burgeon-
ing health problem that affects one-third of adults and
an increasing number of children in developed countries.
The disease begins with the aberrant accumulation of
triglyceride (TG) in the liver, which in some individuals
elicits an inflammatory response that can progress to cir-
rhosis and liver cancer [1].
The earliest stage of NAFLD is hepatic steatosis, which
is characterized by the deposition of TG as lipid droplets
in the cytoplasm of hepatocytes, and the presence of
cytoplasmic TG droplets in more than 5% of hepatocytes
[2]. The hepatic steatosis is often limited. However,* Correspondence: zhangxiuying@neau.edu.cn
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stated.approximately 10%-30% of patients with hepatic steatosis
develop nonalchoholic steatohepatitis (NASH) [3], pre-
valent among a largely middle-aged population and
distinguished from SS by the presence of hepatocyte bal-
looning, cell death, inflammation, and/or fibrosis. Subse-
quently, between 10 and 29% of patients with NASH
progress to cirrhosis [4] and 4 to 27% of patients with
NASH-induced cirrhosis develop hepatocellular carcin-
oma [5]. NASH is the key stage in the progression of
NAFLD but what causes the transition from SS to
NASH is unclear.
Nuclear erythroid 2-related factor 2 (Nrf2) is a signifi-
cant transcription factor for the induction of a variety of
detoxification enzymes, biotransformation enzymes, and
xenobiotic efflux transporters, which can regulate up or
down inflammatory cytokine genes, fibrogenesis-relatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Comparison of Nrf2 with respect to body weight, liver
weight, and liver-body. a. The influence of Nrf2 deletion on mice
body weight. b. The influence of Nrf2 deletion on mice liver weight.
c. The influence of Nrf2 deletion on mice rate of liver and body.
Data are expressed as mean ± SD of 5 mice per group. Asterisks *
represent statistical difference caused by HFD within WT and null-
Nrf2 groups; dollar signs $ represent statistical difference from WT
and null-Nrf2 on the same diet. 0.05 < P values < 0.01 (*, $). P values
< 0.01 (**, $$). The same illustrations are used in the following
figures that are applicable.
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tional pathway. It has been proposed that the Nrf2 gene
plays a role in NASH because deleting it from mice re-
sults in rapid onset and progression of the disease [6].
However, whether Nrf2 plays a role in the transition
from SS to NASH induced by a high-fat diet (HFD) has
been unclear. We hypothesize that Nrf2 does play a role
and that deletion of Nrf2 will make SS develop into
NASH induced by HFD in the short term. To test the
hypothesis, we have analyzed and evaluated biochemical
and pathological characteristics and the expression levels
of genes involved in inflammatory cytokine in the livers
of wild-type (WT) and Nrf2-null mice that are placed on
a HFD, a proven method of stimulating NAFLD in ro-
dents [7]. Moreover, the studies test the content and ra-
tio of fatty acids in the liver, in order to explore the
function of fatty acid in the progression. By using Nrf2-
null mice fed an HFD, we first demonstrated that Nrf2
deletion led to the development of NASH from SS, a re-
sult that was impossible to produce in the WT induced
by HFD over a period of four weeks. The contents of
SFA (C20: 0, C22: 0) and MUFA (C18: 1, C20: 1) in-
creased, and the ratios of PUFA and MUFA in SFA
homeostasis are important in bringing about the pro-
gression of SS to NASH.
Materials and methods
Animals and experimental design
WT and Nrf2-null mice, all 8-week-old male with ICR
background were fed an HFD [8] or control diet for
4 weeks. At the end of the experiment, serum and liver
tissue specimens were collected for analysis. All experi-
ments were performed under protocols approved by
the Institutional Animal Care and Use Committees of
Northeast Agricultural University.
Histological analysis
Sections (approx 4 μm) of formalin-fixed and paraffin-
embedded liver tissue were stained with hematoxylin
and eosin before being examined under a light micro-
scope. Scoring for the degree of steatosis, inflammation,
and fibrosis in the livers of all mice was carried out by a
pathologist who was unaware of the genotypes of the mice
and whether they had been fed the HFD or control diet.
Biochemical analysis
Blood specimens were collected immediately before sac-
rifice after a 4-hour fast and tested for plasma alanine
aminotransferase (ALT), cholesterol (TC), total triglycer-
ide (TG), aspartate transminase (AST), alkaline (ALP),
glucose (GLU), and very low-density lipoprotein (VLDL),
which were determined using a Beckman CX4 automatic
biochemical analyzer (Beckman Coulter, Inc., USA).Lipid analysis
Measurement of the fatty acid content of the liver
specimens was carried out using gas chromatography
mass spectrometry (GC-MS) (HP6890N-5973 Agilent,
Hewlett-Packard, USA) [8].
Real-time quantitative polymerase chain reaction
Total RNA was isolated from whole liver tissue using
RNeasy Mini Columns (Qiagen, Valencia, CA) and re-
verse transcribed to complementary DNA. Quantitative
real-time reverse-transcription polymerase chain reac-
tion (RT-PCR) was performed using the ABI 7500
sequence detection system. Assays were performed in
triplicate, and results were expressed as relative gene ex-
pression normalized to expression levels of housekeep-
ing gene (GAPDH).
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Results were expressed as proportion or means ± stand-
ard deviation (SD). Mean values of normally distributed
continuous variables were compared using a t test. A P
value <0.05 was considered statistically significant. We
performed formal statistics for two comparisons: the
control versus the HFD group on the same genotypes
and WT versus Nrf2-null groups on the same diet.
Results
Nrf2 deletion causes greater liver weight gain in the
Nrf2-null than in the WT mice
In feeding with HFD, the body weight, liver weight, and
liver-body weight ratio of the WT and Nrf2-null mice
were increased (Figure 1). In contrast to WT mice, the
magnitude of the body weight increase in the Nrf2-null
mice was lower (Figure 1a), but their liver-body weight
ratio increase (2.78 ± 0.56%) were greater than those in
the Nrf2-null mice ( 3.06 ± 0.28%) (Figure 1c).
Nrf2 deletion causes histological fibrosing steatohepatitis
in the mice fed the high fat diet for 4 weeks
Histopathological examination revealed no evidence of
inflammation in livers from WT-control, Nrf2-null-
control, and WT-HFD mice. The livers from WT-HFD
mice showed micro-lipid droplets and about 20%Figure 2 Comparison of Nrf2 with respect to liver histopathology. Fre
and flammatory cell. a. Wide type mouse liver induced by control diet. b. W
hepatosteatosis consisting of mixed microvesicular and macrovesicular fat
mild granular degeneration. d. Nrf2-null mouse liver induced by high fatty
sicular fat accumulation, and mild inflammatory cell infiltration. Arrow indicsteatosis in the liver, whereas there was evidence of
macro-lipid droplets and up to 80% steatosis in hepato-
cytes and inflammatory cell infiltration in the liver of
Nrf2-null-HFD mice (Figure 2).Nrf2 deletion increases plasma levels of liver enzymes
Plasma levels of liver enzymes and other chemicals in
mice with SS or NASH are shown in Figure 3. The HFD
induced the serum ALT, AST, ALP, GLU, and VLDL
levels elevated in the mice of both genotypes. Nrf2
deletion caused the increased tendency of serum ALT
and ALP whichenhanced, but the increased tendency of
serum TC, AST, and VLDL weakened. ALT and ALP
levels in Nrf2-null-HFD group (165.33 ± 14.97u/L;
430.67 ± 22.03 u/L) were significantly higher than those
in WT-HFD group (135.67 ± 10.96u/L; 192.33 ± 19.14u/L).
However, the serum TC, AST, and VLDL levels in
Nrf2-null-HFD groups (7.81 ± 0.23 mmol/L; 336.33 ±
13.65u/L; 0.88 ± 0.45 mmol/L) were significantly lower
than those in WT-HFD group (11.33 ± 1.39 mmol/L;
439.67 ± 44.16u/L; 1.12 ± 0.28 mmol/L). The serum
glucose level was similar in the mice of both genotypes
(8.56 ± 0.31 mmol/L; 8.53 ± 0.46 mmol/L). HFD caused
the serum TG level to be elevated in Nrf2-null mice,
but lowered in WT.sh sections were stained with H & E to demonstrate lipid accumulation
ide type mouse liver induced by high fatty diet with mild
accumulation. c. Nrf2-null mouse liver induced by control diet with
diet with severe and large scale hepatosteatosis consisting of macrove-
ates infiltrated inflamematory cells.
Figure 3 Comparison of Nrf2 with respect to plasma laboratory tests; a. The contents of ALT in the serum; b. The contents of AST in the
serum; c. The contents of ALP in the serum; d. The contents of GLU in the serum; e. The contents of VLDL in the serum; f. The contents of TC in
the serum; g. The contents of TG in the serum. ALT, alanine transaminase; AST, aspartate transminase; ALP, alkaline; GLU, glucose; VLDL, very low
density lipoprotein; TC, total cholesterol; TG, triglyceride.
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liver
The hepatic fatty acid composition of mice with SS or
NASH is given in Table 1. The concentrations of C16:
0, C17: 0, C18: 0, C18: 1, C18: 2, C20: 1, C20: 2, C20:
3, C20: 4, and C22: 0 increased significantly in both
mouse genotypes induced by HFD (p < 0.05). The con-
centrations of C18: 1, C20: 1, and C22: 0 in the Nrf2-
null-HFD group were significantly higher than those
in the WT-HFD group (p < 0.05). The HFD caused theconcentrations of C12: 0, C15: 0, C18: 3, and C20: 0 to
increase significantly in Nrf2-null mice (p < 0.05),
but there was no significant difference in WT mice
(p < 0.05). The HFD caused the concentrations of C14: 0
and C22: 6 to decrease in both mouse genotypes. Nrf2
deletion caused the reduction of C22: 6 in Nrf2-null
mice compared with WT mice. The concentrations of
TFA, SFA, UFA, PUFA, and MUFA were increased
significantly in both mouse genotypes with HFD
(p < 0.01). The concentration of UFA in the Nrf2-null-
Table 1 The fatty acid content and ratios in the mice liver
Fatty acid WT-control WT-HFD Nrf2-null-control Nrf2-null-HFD
C12: 0 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.08 ± 0.01**
C14: 0 0.14 ± 0.01 0.13 ± 0.01 0.22 ± 0.02$$ 0.19 ± 0.02$$
C15: 0 0.12 ± 0.01 0.13 ± 0.01 0.12 ± 0.01 0.14 ± 0.01*
C16: 0 5.64 ± 0.48 10.56 ± 0.78** 5.98 ± 0.54 11.59 ± 0.95**
C17: 0 0.07 ± 0.01 0.11 ± 0.01** 0.08 ± 0.01 0.12 ± 0.01**
C18: 0 4.17 ± 0.28 5.10 ± 0.41* 4.30 ± 0.37 5.46 ± 0.49*
C18: 1 7.46 ± 0.64 13.35 ± 1.16** 7.66 ± 0.67 17.40 ± 1.36**$$
c18: 2 5.13 ± 0.39 7.34 ± 0.59** 5.30 ± 0.39 8.13 ± 0.68**
C18: 3 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 0.04 ± 0.00*
C20: 0 0.08 ± 0.01 0.10 ± 0.01 0.09 ± 0.01 0.15 ± 0.01**$$
C20: 1 0.08 ± 0.01 0.10 ± 0.01** 0.08 ± 0.01 0.12 ± 0.01**$
C20: 2 0.18 ± 0.01 0.31 ± 0.03** 0.19 ± 0.02 0.32 ± 0.03**
C20: 3 0.29 ± 0.03 0.38 ± 0.03** 0.30 ± 0.03 0.40 ± 0.03**
C20: 4 2.55 ± 0.21 3.26 ± 0.31** 2.74 ± 0.03 3.46 ± 0.32*
C22: 0 0.02 ± 0.00 0.03 ± 0.01* 0.03 ± 0.00 0.05 ± 0.01**$$
C22: 6 0.85 ± 0.06 0.57 ± 0.03** 0.68 ± 0.05 0.64 ± 0.05
TFA 26.88 ± 2.17 41.57 ± 3.41** 27.87 ± 2.38 48.31 ± 3.99**$
SFA 10.32 ± 0.75 16.23 ± 1.18** 10.89 ± 0.91 17.79 ± 1.44**
UFA 16.56 ± 0.91 25.34 ± 1.56** 16.98 ± 1.28 30.51 ± 2.30**$
PUFA 9.03 ± 0.36 11.90 ± 0.49** 9.25 ± 0.63 12.99 ± 0.98**
MUFA 7.53 ± 0.63 13.45 ± 1.15** 7.73 ± 0.68 17.52 ± 1.36**$$
SFA/TFA ratio (%) 38.37 ± 0.57 39.08 ± 0.37 39.24 ± 0.54 36.83 ±0.36**$$
UFA/TFA ratio (%) 61.62 ± 0.57 60.97 ± 0.37 60.93 ± 0.54 63.16 ± 0.36**$$
PUFA/SFA ratio (%) 87.69 ± 4.63 73.45 ± 3.39** 85.05 ± 3.57 73.07 ± 2.42**
MUFA/SFA ratio (%) 72.99 ± 0.83 82.80 ± 1.11** 71.02 ± 0.34 98.48 ± 0.34**$$
n-6 / n-6 ratio (%) 49.94 ± 6.59 43.49 ± 5.78 50.47 ± 2.98$$ 42.65 ± 3.89*
Asterisks * represent statistical difference caused by HFD within WT and null-Nrf2 groups; dollar signs $ represent statistical difference from WT and null-Nrf2 on
the same diet. 0.05 < P values < 0.01 (*, $). P values < 0.01 (**, $$).
All of the values are expressed as mean ± standard deviation (SD) (n = 20 per treatment group). TFA, total fatty acid; SFA, saturated fatty acid; UFA, unsaturated
fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid; n-6/n-6 ratio, C20: 4/C18: 2.
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HFD group (p < 0.05), due to the significantly in-
creased concentration of MUFA in the Nrf2-null-HFD
group (p < 0.01) compared with the WT-HFD group.
The HFD caused the SFA/TFA ratio and UFA/TFA ra-
tio increase in Nrf2-null mice, but not in WT mice.
The PUFA/SFA ratio decreased (p < 0.01) and the
MUFA/SFA ratio increased in both mouse genotypes
with HFD (p < 0.01). In contrast to the WT-HFD
group, Nrf2 deletion caused the MUFA/SFA ratio to
increase significantly (p < 0.01), while the PUFA/SFA
ratio did not rise significantly in Nrf2-null-HFD group
(p > 0.05). The HFD caused the n-6/n-6 ratio reduc-
tion in both mouse genotypes and Nrf2 deletion
caused a more significant downward trend compared
with WT mice.Hepatic messenger RNA studies suggest that Nrf2
deletion causes NASH happened by coordinating with
up-regulating IL-1β, IL-6 and TNF-α
The Nrf2 deletion caused the IL-1β, IL-6, and TNF-α ex-
pression to increase in mice with HFD (Figure 4). Fed
with the control diet, genotypes could influence the IL-
1β, IL-6, and TNF-α expression. Nrf2 deletion mice had
lower expressions of IL-1β, IL-6, and TNF-α than WT
mice. The HFD-induced IL-1β expression was not sig-
nificantly different in WT and Nrf2-null mice, but the
gain of IL-1β expression in Nrf2-null mice was higher
than in WT mice. HFD induced the IL-6 expression up-
regulation in both mouse genotypes, which increased
significantly in Nrf2-null mice (Figure 4b). The TNF-α
expression was down-regulation in WT induced by
HFD, but regulated up in Nrf2-null mice (Figure 4c).
Figure 4 Comparison of Nrf2 with respect to Messenger RNA expression of Nrf2, IL-1, IL-6, and TNF-α in liver. a. The influence of Nrf2
deletion on the IL-1 mRNA expression in liver. b. The influence of Nrf2 deletion on IL-6 mRNA expression in liver. c. The influence of Nrf2 deletion
on TNF-αmRNA e xpre ssion in liver. d. The mRNA expression in the mice of both genotypes induced by control diet and high fat diet. Nrf2,
nuclear factor erythoid 2-related factor 2; IL-1, interleukin-1; IL-6, interleukin-6; TNF-α, tumor necro sis factor a lpha.
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cantly (Figure 4d).
Discussion
Hepatic simple steatosis (SS) is characterized by the de-
position of TG droplets in more than 5% of hepatocytes;
and 10-30% of patients will develop nonalchoholic stea-
tosis hepatitis (NASH). Our results suggest that the Nrf2
gene interacts strongly in the progression of SS to
NASH induced by HFD. With feeding the HFD, Nrf2
deletion caused TG deposits in about 80% of hepato-
cytes, and the introduction of inflammatory cells into
the liver. In contrast, the WT mice, had no inflamma-
tory cells and had TG deposits in only 20% of hepato-
cytes (Figure 1). From liver pathology, it was determined
that Nrf2-null mice had developed NASH, and that it
had been induced by 4 weeks of HFD diet. The mechan-
ism of hepatic accumulation of TG is attributed to both
an increased uptake of fatty acid and a reduced TG se-
cretion via VLDL [7]. HFD can cause increased uptake
of fatty acid and is proven as a valuable approach to
mimic NAFLD in mice [9,10]. From Figure 2, the serum
TG concentration increased in Nrf2-null mice and de-
creased in WT mice. The serum VLDL concentration,
which assists with TG secretion, was increased in both
mouse genotypes; however, the increased gain in VLDLconcentration in Nrf2-null mice was lower than in WT
mice. This suggests that Nrf2 deletion promoted hepatic
fat accumulation through a decrease of the TG secretion
via VLDL. Our results reinforce the commonly held belief
that Nrf2 can inhibit fat accumulation in the liver [7].
Hepatic lipid accumulation can induce insulin resist-
ance, lipid peroxidation, hepatic cell damage, and in-
flammation [11]. Researchers compared the plasma fatty
acid of NASH patients and control patients and found
that NASH patients had a significantly higher concentra-
tion of free fatty acid (FFA), higher total saturated and
monounsaturated levels in both lipid fractions and in-
creased hexadecanoic acid and octadecenoic acid levels
(C16: 0 and C18: 1) compared with control patients [12].
Similar profiles of FFA, SFA, and MUFA were found in
our study. The FFA, SFA, and MUFA all increased with
SS and NASH, but the TFA and MUFA concentrations
in NASH were significantly higher than those in SS
(Table 1). SFA (16: 0 and 18: 0) accumulation in hepato-
cytes could increase stress in the endoplasmic reticulum
and cause hepatocyte injury [13]. Surprisingly, the
excessive accumulation of SFA, eicosanoic acid and
docosanoic acid (C20: 0 and C22: 0), in hepatocytes
could trigger progression of SS to NASH (Table 1).
Octadecenoic acid and eicosenoic acid (C18: 1 and
C20: 1) concentrations in the HFD-Nrf2-null group were
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suggests that C18: 1 and C20: 1 contributed to the pro-
gression of SS to NASH. Progressive increase in MUFA
is associated with the severity of the hepatic lesion [14].
PUFA forms precursors to both pro- and anti-
inflammatory molecules. The balance between these mu-
tually antagonistic compounds could determine the final
outcome of disease processes [11] and play a protective
role by controlling synthesis and oxidation of SFA and
MUFA [15]. Our studies found that the PUFA concen-
trations increased in the course of SS and NASH, except
docosahexanoic acid (C22: 6). HFD induced the C22: 6
decrease in the liver, which could be suppressed by Nrf2
deletion (Table 1). C22: 6 can suppress IL-1β and TNF-a
production [16]. We considered that the result of in-
creasing of C22: 6 was to resist oxidation and inflamma-
tion of the increasing SFA and MUFA in the HFD-Nrf2-
null group through the suppression of IL-1β and TNF-a
in contrast to the HFD-WT group. In addition, docosa-
hexanoic acid, linolenic acid, and dihomo-linolenic acid
(C22: 6, C18: 3, and C20: 3) as endogenous anti-
inflammatory molecules can suppress IL-1β, TNF-a, and
IL-6 production by T cells [17-22]. From Table 1, the
concentration of C18: 3 in the HFD-Nrf2-null group
were significantly higher than that in the HFD-WT
group. Interestingly, the inflammatory cytokines IL-1β,
TNF-a, and IL-6 expression increased significantly
(Figure 4) and induced insulin resistance (Figure 3d) in
the HFD-Nrf2-null group, compared with the HFD-WT
group. Our finding suggests that IL-1β, TNF-a and IL-6
expression resulted in the significant increase of the
SFA/TFA ratio and the MUFA/SFA ratio and the de-
crease of the PUFA/SFA ratio in the HFD-Nrf2-null
group compared to the HFD-WT group (Table 1). In
NASH, many pro-inflammatory cytokines are abnormal
expressions [23]. The expression of TNF-a and TNF-a
type 1 receptors in patients with steatohepatitis is
greater than for those with steatosis alone [24,25]. The
dramatic increase of TNF-a is an important function in
the progression of steatosis to NASH.
The two-hit theory proposed by Day and James [26] is
widely advocated as a pathologic mechanism for steato-
hepatitis. This theory claims that in addition to steatosis
(the first hit) the development of steatohepatitis requires
the presence of some other factors (the second hit). Ac-
cording to our results, the HFD, as the first hit, caused
the superfluous TG accumulation in liver, the lipid drop-
lets in the hepatocytes. The disrupted hepatic fatty acid
promoted hepatic pro-inflammatory cytokines and pro-
inflammatory molecules in the liver, leading to the sec-
ond hit. Our studies suggest that the deletion of Nrf2, a
lipid-metabolism regulating gene, disrupts fatty acid
composition and homeostasis, causing the evolution
of the “benign” SS to develop into NASH, throughregulating of the MUFA/TFA ratio up and the PUFA/
TFA ratio down, in conjunction with the increased hep-
atic concentrations of C18: 1, C20: 1, C12: 0, C22: 0, and
C18: 3 in the liver. Whether the blood serum levels of
fatty acids and their ratios are consistent with those in
the liver needs to be determined in future studies.
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